N-acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery

Critical Care Medicine

Volumn 37, Issue 6, 2009, Pages 1929-1934

  Wijeysundera, Duminda N ^a   Karkouti, Keyvan ^a   Rao, Vivek ^a   Granton, John T ^b   Chan, Christopher T ^b   Raban, Roshan ^a   Carroll, Jo ^a   Poonawala, Humara ^a   Beattie, W Scott ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Blood transfusion; Cardiac surgery; Cardiopulmonary bypass; Hemorrhage; Hemostasis; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOSTASIS; HUMAN; INFLAMMATION; ISCHEMIA; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; TUBE; AGED; DOUBLE BLIND PROCEDURE; DRUG EFFECT; STATISTICS;

ACETYLCYSTEINE; AGED; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEMOSTASIS; HUMANS; MALE;

EID: 66449084804     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819ffed4     Document Type: Article

References (32)

1. Bagshaw SM, McAlister FA, Manns BJ, et al: Acetylcysteine in the prevention of contrast-induced nephropathy: A case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006; 166:161-166
2. Burns KE, Chu MW, Novick RJ, et al: Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: A randomized controlled trial. JAMA 2005; 294:342-350
3. El-Hamamsy I, Stevens LM, Carrier M, et al: Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: A randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2007; 133:7-12
4. Haase M, Haase-Fielitz A, Bagshaw SM, et al: Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007; 35:1324-1331
5. Hynninen MS, Niemi TT, Poyhia R, et al: N-Acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: A randomized, double-blind, placebo-controlled trial. Anesth Analg 2006; 102:1638-1645
6. Ozaydin M, Peker O, Erdogan D, et al: N-Acetylcysteine for the prevention of postoperative atrial fibrillation: A prospective, randomized, placebo-controlled pilot study. Eur Heart J 2008; 29:625-631
7. Ristikankare A, Kuitunen T, Kuitunen A, et al: Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006; 97:611-616
8. Sisillo E, Ceriani R, Bortone F, et al: N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: A prospective, randomized, clinical trial. Crit Care Med 2008; 36:81-86
9. Tossios P, Bloch W, Huebner A, et al: N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg 2003; 126:1513-1520
10. Vento AE, Nemlander A, Aittomaki J, et al: N-Acetylcysteine as an additive to crystalloid cardioplegia increased oxidative stress capacity in CABG patients. Scand Cardiovasc J 2003; 37:349-355
11. Sajja LR, Mannam G, Chakravarthi RM, et al: Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: A randomized study. J Thorac Cardiovasc Surg 2007; 133:378-388
12. Niemi TT, Munsterhjelm E, Poyhia R, et al: The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul Fibrinolysis 2006; 17: 29-34
13. Karkouti K, Wijeysundera DN, Yau TM, et al: The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44:1453-1462
14. Anderson RJ, O'Brien M, MaWhinney S, et al: Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55:1057-1062
15. Wijeysundera DN, Beattie WS, Rao V, et al: N-Acetylcysteine for preventing acute kidney injury in cardiac surgery patients with preexisting moderate renal insufficiency. Can J Anesth 2007; 54:872-881
16. Wijeysundera DN, Karkouti K, Beattie WS, et al: Improving the identification of patients at risk of postoperative renal failure after cardiac surgery. Anesthesiology 2006; 104: 65-72
17. Andersen LW, Thiis J, Kharazmi A, et al: The role of N- acetylcysteine administration on the oxidative response of neutrophils during cardiopulmonary bypass. Perfusion 1995; 10: 21-26
18. Cheng DC, Karski J, Peniston C, et al: Early tracheal extubation after coronary artery bypass graft surgery reduces costs and improves resource use. A prospective, randomized, controlled trial. Anesthesiology 1996; 85:1300-1310
19. Karkouti K, Yau TM, van Rensburg A, et al: The effects of a treatment protocol for cardiac surgical patients with excessive blood loss on clinical outcomes. Vox Sang 2006; 91:148-156
20. Efron B, Tibshirani RJ: An Introduction to the Bootstrap. New York, Chapman & Hall, 1994
21. Karkouti K, O'Farrell R, Yau TM, et al; Reducing Bleeding in Cardiac Surgery Research Group: Prediction of massive blood transfusion in cardiac surgery. Can J Anesth 2006; 53:781-794
22. Tong IS, Lu Y: Identification of confounders in the assessment of the relationship between lead exposure and child development. Ann Epidemiol 2001; 11:38-45
23. Localio AR, Margolis DJ, Berlin JA: Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol 2007; 60: 874-882
24. R Development Core Team: R: A language and environment for statistical computing. Available at: www.R-project.org. Accessed July 1, 2007
25. Fergusson D, Aaron SD, Guyatt G, et al: Post-randomisation exclusions: The intention to treat principle and excluding patients from analysis. BMJ 2002; 325:652-654
26. Laupacis A, Sackett DL, Robers RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318:1728-1733
27. Anfossi G, Russo I, Massucco P, et al: N-Acetyl-L- cysteine exerts direct anti-aggregating effect on human platelets. Eur J Clin Invest 2001; 31:452-461
28. Knudsen TT, Thorsen S, Jensen SA, et al: Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in health subjects. Gut 2005; 54:515-521
29. Karkouti K, Wijeysundera DN, Beattie WS, et al: Variability and predictability of large-volume red blood cell transfusion in cardiac surgery: A multicenter study. Transfusion 2007; 47:2081-2088
30. Brotman DJ, Walker E, Lauer MS, et al: In search of fewer independent risk factors. Arch Intern Med 2005; 165:138-145
31. DiMari J, Megyesi J, Udvarhelyi N, et al: N-Acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 1997; 272:F292-F298
32. Marenzi G, Assanelli E, Marana I, et al: N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354:2773-2782